Endovascular Treatment of Intracranial Vein and Venous Sinus Thrombosis—A Systematic Review

Philipp Bücke 1,*, Victoria Hellstern 2, Alexandru Cimpoca 2, José E. Cohen 3, Thomas Horvath 1, Oliver Ganslandt 4, Hansjörg Bäzner 5 and Hans Henkes 2,6

1 Department of Neurology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; thomas.horvath@insel.ch
2 Neuroradiologische Klinik, Klinikum Stuttgart, 70174 Stuttgart, Germany; v.hellstern@klinikum-stuttgart.de (V.H.); a.cimpoca@klinikum-stuttgart.de (A.C.); h.henkes@klinikum-stuttgart.de (H.H.)
3 Department of Neurosurgery, Hadassah Medical Center, Hebrew University Jerusalem, Jerusalem 9103401, Israel; jcohenns@yahoo.com
4 Neurochirurgische Klinik, Klinikum Stuttgart, 70174 Stuttgart, Germany; o.ganslandt@klinikum-stuttgart.de
5 Neurologische Klinik, Klinikum Stuttgart, 70174 Stuttgart, Germany; h.baezner@klinikum-stuttgart.de
6 Medical Faculty, Universität Duisburg-Essen, 45147 Essen, Germany
* Correspondence: philipp.buecke@insel.ch

Abstract: Background: Cerebral venous sinus or vein thromboses (SVT) are treated with heparin followed by oral anticoagulation. Even after receiving the best medical treatment, numerous patients experience neurological deterioration, intracerebral hemorrhage or brain edema. Debate regarding whether endovascular treatment (EVT) is beneficial in such severe cases remains ongoing. This systematic review summarizes the current evidence supporting the use of EVT for SVT on the basis of case presentations, with a focus on patient selection, treatment strategies and the effects of the COVID-19 pandemic. Methods: This systemic literature review included randomized controlled trials (RCTs) and retrospective observational data analyzing five or more patients. Follow-up information (modified Rankin scale (mRS)) was required to be provided (individual patient data). Results: 21 records (n = 405 patients; 1 RCT, 20 observational studies) were identified. EVT was found to be feasible and safe in a highly selected patient cohort but was not associated with an increase in good functional outcomes (mRS 0–2) in RCT data. In observational data, good functional outcomes were frequently observed despite an anticipated poor prognosis. Conclusion: The current evidence does not support the routine incorporation of EVT in SVT treatment. However, in a patient cohort prone to poor prognosis, EVT might be a reasonable therapeutic option. Further studies determining the patients at risk, choice of methods and devices, and timing of treatment initiation are warranted.

Keywords: cerebral venous sinus thrombosis; endovascular therapy; thrombolysis; thrombectomy; intracerebral hemorrhage; anticoagulation; VITT

1. Introduction

Cerebral venous sinus or venous thrombosis (SVT) is a rare but potentially severe cause of cerebral hemorrhage or cerebral venous infarction (incidence: 1.32 per 100,000 person-years (2.78 per 100,000 person-years in women 31–50 years of age)) accounting for approximately 0.5% of all stroke cases [1–3]. Various factors are associated with the development of SVT [1,4]. Recent publications have reported a considerably higher incidence of SVT in the COVID-19 pandemic because both COVID-19 (reported incidence: 8.8 per 10,000 infections over 3 months) and COVID-19 vaccination (leading to vaccine-induced immune thrombotic thrombocytopenia (VITT)) appear to increase the risk of SVT [5,6]. Figure 1 illustrates the anatomy of the cerebral dural sinus and the deep cerebral veins.
Outcomes after SVT in general are favorable assuming early diagnosis and treatment initiation [8]. Treatment is challenging, and its success highly depends on rapid anticoagulation with unfractionated or low-molecular-weight heparin, even in cases of intracerebral hemorrhage [9,10]. However, probably because of a limited capacity to dissolve an extensive intravenous thrombus load, many patients show deterioration, and as many as 13% eventually die or remain severely disabled despite sufficient anticoagulation therapy [11–13]. Patients with coma or altered mental status, intracerebral hemorrhage (ICH), underlying malignancy or an infection of the central nervous system appear to be at risk [12]. Pregnant or postpartum women, chronic hypertension as well as superior sagittal sinus and cortical vein involvement seem to be associated with ICH complications in SVT [14].

Endovascular treatment (EVT) strategies have been proposed to increase the frequency of good functional outcomes in high-risk or deteriorating patients [15–25]. Initially, endovascular thrombolysis with application of the thrombolytic agent locally and at the site of the occluded sinus was described [15,16]. Occasionally, the catheter is left in situ for 24 h or more [16,17]. In addition, several endovascular techniques have been discussed and investigated: rheolytic catheter thrombectomy, direct aspiration thrombectomy, balloon-guided thrombectomy or angioplasty and stent retriever thrombectomy [18–37]. Information on EVT in SVT is sparse and is based primarily on case series and anecdotal data and only a single published randomized controlled trial (RCT) [19,38–57]. Therefore, the current guideline recommendations remain vague. Whereas the American Heart Association and the American Stroke Association have together stated that endovascular therapy “may
be considered if deterioration occurs despite intensive anticoagulation treatment,” the European Stroke Organisation has not given any advice at all [58,59].

The goal of this systematic review is to provide an overview on the current evidence supporting EVT strategies in patients with SVT. We aimed to identify potential selection criteria for patients who might benefit from an additional EVT. Furthermore, the roles of SARS-CoV-2 infections and VITT are discussed.

2. Materials and Methods

We performed a systematic literature search in the PubMed (20 May 2022) and Medline (20 May 2022) databases by using the following search terms: “sinus thrombosis AND endovascular,” “sinus thrombosis AND thrombectomy,” “[cerebral] venous thrombosis AND endovascular” and “[cerebral] venous thrombosis AND thrombectomy.” For the sub-analysis of patients with SVT caused by SARS-CoV-2 infection or after COVID-19 vaccination, additional search phrases were identified: “COVID-19 AND endovascular (AND thrombosis),” “COVID-19 AND thrombectomy (AND thrombosis),” “vaccination AND endovascular” and “vaccination AND thrombectomy.” All articles published online until 20 May 2022 were screened. Two independent raters performed the literature search (P.B. and H.H.). This review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) recommendations [60].

All identified publications were required to meet the following predefined inclusion criteria: (1) RCTs or retrospective studies, case series/case reports including more than five patients 18 years of age or older; (2) reported information on functional outcomes (modified Rankin scale (mRS) after discharge (not at the time of discharge)), death and complications (e.g., symptomatic intracranial hemorrhage or procedural complications); (3) inclusion of individual patient or study data only once (screening for repeated publications including identical cases); and (4) publication in English. In the analysis of EVT in patients with COVID-19 and VITT, only articles and manuscripts evaluating endovascular procedures (and the respective indications to treat patients) were eligible. We, therefore, did not consider registry data and meta-analyses reporting the frequency and the number of interventions without mentioning procedure-specific outcome parameters.

3. Results

A total of 456 records were identified and screened on the basis of the predefined search criteria (Figure 2). Only 92 were eligible for full-text evaluation. Eventually, 21 records were eligible for inclusion (reasons for exclusion of records: \( n = 56 \)—case reports or case series with fewer than five reported events; \( n = 14 \)—no follow-up data or data on functional outcomes; \( n = 3 \)—not written in English).

![Flow diagram visualizing the selection process for the included publications.](image-url)
One RCT (Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis; TO-ACT) compared EVT ($n = 33$) and standard care (i.e., anticoagulation; $n = 34$) in patients with anticipated poor outcomes (Table 1) [38], which were defined as at least one of the following risk factors: mental status disorder, coma state (Glasgow coma scale (GCS) < 9), ICH or thrombosis of the deep cerebral venous system. Patients with more than 10 days from diagnosis to potential randomization, pregnancy (women in the puerperium were eligible), thrombocytopenia (platelet count < $100 \times 10^9$/$L$), as well as clinical or radiological signs of impending trans-tentorial herniation were excluded. EVT (mechanical thrombectomy with an AngioJet (Boston Scientific, Marlborough, MA, USA), stent retriever, aspiration techniques or microcatheter) in combination with local thrombolytic treatment (urokinase administered continuously for up to 72 h) did not differ from standard care in terms of functional outcomes (mRS, 0–1 at 12 months; 67% vs. 68%; risk ratio, 0.99 (95% CI, 0.71–1.18); Table 1 provides details and information on complications).

Nyberg et al. (2017) have retrospectively analyzed their single-center cohort of patients with SVT and compared outcome data (mRS, 0–2 at 3 months) for patients treated with additional EVT ($n = 29$) to those receiving anticoagulation only ($n = 37$; 5-year time span (2011–2015)) [39]. The decision on whether to perform EVT was at the discretion of the treatment team and based on individual decision-making. The two treatment groups did not differ in outcome parameters (e.g., mRS, 0–2: 22% vs. 30%; mortality, $n = 6$ vs. $n = 5$; $p = 1.0$).

Prospective case series, retrospective analyses and case series demonstrated the technical and procedural feasibility and safety of EVT in selected patients ($n = 19$; details in Table 1) [19,40–57]. All reported patients were anticoagulated, and those with an expected poor prognosis (such as ICH or edema, neurological deterioration, coma (e.g., GCS < 9), progressive thrombus material observed on repeated imaging or signs of elevated intracranial pressure (e.g., papilledema)). Individual decision-making based on local experience and preferences was used to decide whether to perform EVT.

A total of 25 publications met the search criteria for COVID-19 and VITT-associated EVT in SVT. Of those, 14 records were excluded (because of lack of reported patient data, review articles and registry data without information on individual patients). Eleven records were eligible for analysis (Table 2) [61–71], comprising case reports and case series only. Of those, four case reports and case series presented data for four patients with COVID-19 and EVT [61–64]. The decision to perform EVT was made in cases with suspected poor prognosis, with criteria comparable to those described above. Aspiration in combination with local thrombolytic therapy was the preferred endovascular technique [61,62]. The overall outcome was poor [61–63].

The first reports of SVT caused by VITT emerged in 2021 [65–71]. As of 20 May 2022, seven records of EVT in 16 VITT patients were identified [65–71]. Most cases ($n = 15$) were attributed to the ChAdOx1 nCoV-19 (AstraZeneca, Cambridge, UK) vaccine [65–67,69–71]. Only one case appeared to be associated with an mRNA vaccine (mRNA-1273 vaccine; Moderna, Cambridge, MA, USA) [68]. Excluding the latter, the time between vaccination and symptom onset was 4–27 days. Common features (except [68]) were thrombocytopenia, elevated D-dimer levels, and positivity for platelet factor 4 (PF4) antibodies (Table 2). Neurological deterioration potentially resulting in poor outcomes facilitated the use of EVT. The technical strategies described were aspiration plus stent retriever or balloon-guided thrombectomy in selected cases [65–67,69]. MRS of 0–1 was observed in seven patients during follow-up [65,66,69]. Three patients died [65,70].
Table 1. Summary of the 21 records included in this systematic review.

| Study Type | Period | n (N) | Inclusion Criteria/Treatment Allocation | Pro-ICH | Endovascular Treatment | Control Group | FU (Month) | Outcome Assessment | Localization | Complications |
|------------|--------|-------|----------------------------------------|---------|------------------------|---------------|-------------|-------------------|--------------|---------------|
| Costinhuo et al. (2020) [36] | RCT | 2015–2016 | 55 (47) | High probability of poor outcome, at least 1 of the following risk factors: mental status disorder, coma, respiratory failure, severe head injury, or storage of the deep cerebral venous system (exclusion: duration from diagnosis of more than 10 days, pregnancy, women in the puerperium were not eligible); thrombocytopenia (platelet count, <100 × 10^9/L) | n = 22 | n = 3; LT (thrombus aspiration, up to 72 h; n = 17 (52%), MT; n = 30 (95%); AngioJet (A) [n = 14], SR; n = 5; B [n = 3]; aspiration (A) [n = 3]; Penumbra, microcatheter [n = 3], other [n = 9]) | n = 34; standard care | 6, 12 | mRS 0–1 (12 months) n = 22 (67%); n = 25 (68%), risk ratio 0.99 (95% CI 0.71–1.38) | 12 months; n = 4 (12%); [n = 1] (55%) | SS (6–12 months); 79% vs. 52%, 1.52 (1.08–2.23), 96% vs. 86%, 1.13 (0.95–1.33) | n = 23 (70%) | n = 17 (52%) | l = 12 | l = 16 | r = 22 | n = 14 (42%) | n = 6 (18%) | NA |
| Næbø et al. (2017) [39] | retros | 2011–2015 | 29 (66) | SVT (anticoagulation), decision of treatment team in the puerperium | n = 17 (n = 10 in CCE) | LT n = 29 (6–72 h), n = 21 additional MT (A, SR, B, AngioJet or combination; not specified) | n = 37; standard care | 3 | mRS 0–2 (p = 1.0) | n = 6 (vs. n = 5) | n = 11; full (n = 9), partial (n = 2) | n = 25 | n = 0 | s = 21 | s = 25 | n = 7 | NN | n = 9 | NN |
| Siddiqui et al. (2014) [40] | retros | 1995–2012 | 63 (NN) | SVT (anticoagulation) and either coma (GCS < 9), ICH or deterioration in either | n = 29 | n = 43, n = 29 LT only, n = 34 MT (plus LT n = 27, AngioJet n = 28, A n = 3, SR n = 1; B n = 2) (LT bolus and continuously depending on recanalization) | NA | 3 | n = 53; mRS 0–1: n = 33 | s = 11 | full (n = 21), partial (n = 18) | NN | NN | NN | NN | NN | n = 5 | n = 3 | NN |
| Guo et al. (2020) [41] | retros | 2010–2019 | 56 (227 se) | SVT under anticoagulation; ICH, lack of improvement or deterioration of symptoms | n = 56 | n = 56, LT only (n = 44, duration 7 days); additional MT (n = 13); SR n = 5, A n = 3, B n = 3, combined n = 8 | NA | 6 | n = 54; mRS 0–2: n = 49 | s = 3 | (full and partial); LT n = 30; MT n = 14 | NN | NN | NN | NN | NN | n = 0 | LT n = 7, MT n = 1 | NN |
| Andersen et al. (2020) [42] | retros | 2007–2018 | 28 (NN) | SVT under anticoagulation; clinical deterioration and/or impaired consciousness | n = 18 | n = 20, LT (n = 20, 12–72 h), A (n = 3), SR (n = 3), combined (more than 2 techniques; n = 4) incl. PTA and stenting (n = 22) | NA | 6 | mRS 0–2: n = 20 | s = 5 | full (n = 15), partial (n = 13); (n = 2) | n = 16 | n = 15 | s = 15 | s = 16 | u = 7 | u = 1 (retrop. hem.) | n = 8 | NA |
| Yang et al. (2019) [43] | pros CS | 2014–2018 | 21 (27 se) | SVT (anticoagulation) with: ICH, mental status impairment, coma (GCS < 9), IV thrombolysis, cortical venous thrombosis, intracranial hypertension, or papilledema | NN | NN | NN | 12 | mRS 0–2: n = 21 | s = 0 | full (n = 5), partial (n = 9) | n = 16 | u = 0 | s = 17 | s = 19 | s = 14 | NN | NN | NN |
### Table 1. Cont.

| Reference | Treatment | Outcome Assessment | Localization | Complications |
|-----------|-----------|--------------------|--------------|---------------|
| Yang et al. (2013) | SVT (anticoagulation) with: deterioration after the initiation of anticoagulation, ischemic or coma, venous infarction with hemorrhagic transformation or ICH | n = 8 | SVT (best medical treatment team) | NA |
| | | | | NA |
| | | | | NA |
| | | | | NA |
| Sun et al. (2016) | SVT (heparin) with: assumed poor prognosis: altered mental status, coma, extensive edema, ICH, infarction | n = 14 | SVT (heparin) with: deterioration after the initiation of anticoagulation, ischemic or coma, venous infarction with hemorrhagic transformation or ICH | NA |
| | | | | NA |
| | | | | NA |
| | | | | NA |
| Lu et al. (2019) | SVT (best medical treatment), decision of treatment team | n = 1 | SVT (best medical treatment team) | NA |
| | | | | NA |
| | | | | NA |
| | | | | NA |
| Qureshi et al. (2018) | SVT (anticoagulation), deterioration | n = 7 | SVT (anticoagulation), deterioration | NA |
| | | | | NA |
| | | | | NA |
| | | | | NA |
| Styrczak et al. (2019) | SVT (heparin) with: assumed poor prognosis: altered mental status or coma, involvement of D, ICH | n = 7 | SVT (heparin) with: deterioration after the initiation of anticoagulation, ischemic or coma, venous infarction with hemorrhagic transformation or ICH | NA |
| | | | | NA |
| | | | | NA |
| | | | | NA |
| Mokan et al. (2019) | SVT (plus/minus anticoagulation), decision of treatment team | NN | SVT (plus/minus anticoagulation), decision of treatment team | NA |
| | | | | NA |
| | | | | NA |
| | | | | NA |
| Doshi et al. (2011) | NA, decision of treatment team | NN | SVT (plus/minus anticoagulation), decision of treatment team | NA |
| | | | | NA |
| | | | | NA |
| | | | | NA |
| Lee et al. (2016) | SVT under anticoagulation; MT in case of ICH, deep venous thrombosis, deterioration | n = 9 | SVT under anticoagulation; MT in case of ICH, deep venous thrombosis, deterioration | NA |
| | | | | NA |
| | | | | NA |
| | | | | NA |
| Poslund et al. (2013) | SVT (anticoagulation) | n = 4 | SVT (anticoagulation) | NA |
| | | | | NA |
| | | | | NA |
| | | | | NA |
Table 1. Cont.

| Author (Year) | Study Type | Period | n (N) | Inclusion Criteria/Treatment Allocation | Pro-ICH | Endovascular Treatment | Control Group | FU (Months) | Outcome | Death | Recanal. | SSS | SS | Sig S | TS | DV | Catherer * | ICH ** | Other |
|---------------|------------|--------|-------|----------------------------------------|---------|------------------------|---------------|--------------|---------|-------|---------|-----|-----|-------|----|-----|----------|-------|-------|
| Mammen et al. (2017) [15] | retrospect | 4 years | 8 (245 sc) | SVT (anticoagulation), no response or deterioration | u = 1 | n = 8 (MT, A [Penumbra]) plus additional B (n = 7) and LT (n = 3, bolus) | NA | 6 | mRS 0-2: x = 5 | u = 1 | full (n = 3), partial (n = 4) | x = 5 | x = 5 | u = 2 | u = 6 | n = 3 | a = 0 | a = 0 | x = 0 |
| Peng et al. (2021) [16] | retrospect | 2017–2020 | 7 (NN) | SVT (anticoagulation); one risk factor (poor outcome): coma (GCS < 9), ICH, DV thrombosis | u = 4 | n = 7 MT (B, plus B A n = 4, plus B B e = 4, plus heparin e = 4, plus LT u = 1 [bolus]) | NA | 3 | mRS 0-2: x = 6 | u = 0 | full (n = 4), partial (n = 3) | x = 7 | u = 0 | u = 4 | u = 5 | n = 0 | a = 0 | a = 0 | x = 0 |
| Mehdi et al. (2020) [17] | retrospect | 2018/2019 | 7 (NN) | SVT (anticoagulation), clinical and imaging deterioration (no signs of formation) | u = 5 | n = 7 (MT, A) plus LT (e = 4, bolus 20 min) | NA | 1 (3, 6) | mRS 0-1: x = 5 | u = 0 | partial (n = 7) | x = 6 | u = 4 | u = 0 | u = 3 | n = 0 | a = 0 | a = 0 | x = 0 |
| Tang et al. (2019) [18] | CS | 2014–2018 | 6 (NN) | SVT (anticoagulation) with deterioration or ICH | NN | u = 6; MT (A [Penumbra]) plus LT (unknow) | NA | 3 | mRS 0-1: x = 5 | u = 1 | N | x = 5 | u = 2 | u = 3 | u = 4 | NN | a = 0 | a = 0 | x = 0 |
| Jankowske et al. (2013) [19] | retrospect | 2009–2011 | 6 (27 sc) | SVT (best medical treatment); clinical (progressive deficits, coma) or radiological (hem., edema) deterioration | u = 4 | n = 6; MT (A) (e = 6), additional LT (n = 4 [bolus]) | NA | 6 | mRS 0-2: x = 4 | u = 1 | x = 6 | x = 3 | u = 2 | u = 1 | u = 5 | NN | a = 0 | NN | x = 0 |
| Yue et al. (2020) [20] | retrospect | 2005–2008 | 6 (28 sc) | SVT (anticoagulation) with deterioration or assumed poor prognostic coma, altered mental state, seizure, space-occupying lesions (edema or [hemorrhage] infarct) | u = 2 | n = 6; MT (B) plus IA (1 [unknow]) | NA | 3 (4) | mRS 0: x = 5 | u = 1 | full (n = 5) | x = 6 | x = 4 | x = 6 | x = 20 | a = 0 | a = 0 | x = 0 |

* catheter complications such as perforation; ** ICH; new hemorrhage or worsening of a pre-existing intracerebral hemorrhage; n, number of patients; N, total number of patients (patients screened: indicated by [sc]; ICH, intracerebral hemorrhage; FU, follow-up; Recanal., recanalization; SSS, sagittal superior sinus; SS, straight sinus; Sig S, sigmoid sinus; TS, transverse sinus; DV, deep cerebral veins; RCT, randomized controlled trial; retrosp, retrospective, pros, prospective; CS, case series; LCS, Glasgow Coma Scale; SVT, sinus or cerebral vein thrombosis; MT, mechanical thrombectomy; NN, unknown; NA, not applicable; LT, local (intrasinus) thrombolysis; A, aspiration thrombectomy; SR, stent retriever thrombectomy; B, balloon guided thrombectomy or angioplasty; PTA, percutaneous transluminal angioplasty; ia, intra-arterial; T, thrombolysis; mRS, modified Rankin Scale; hem, hemorrhagic or hemorrhage; retrosp., retroperitonale; compl, complication; perf, perforation; SAH, subarachnoid hemorrhage; occl, occlusion.

Table 2. Case reports of endovascular therapy in SVT due to COVID-19 or VITT.

| Reference | Etiology | Laboratory Findings | Treatment | Endovascular Treatment | Outcome | Location | Complications |
|-----------|----------|---------------------|-----------|------------------------|---------|----------|---------------|
| Ostovan et al. (2021) [62] | case series | 1 (of 9) | C-19 | TP (140 T/U), elevated D-dimer levels (>10,000 ng/mL) | ICH | LT plus MT (A) | 6 | full | SSS, TS | NN |
Table 2. Cont.

| Reference                          | Study Type | n   | COVID-19 (C-19, VITT) | d (After Index) | Laboratory Findings | Treatment | Endovascular Treatment | Outcome | Location | Complications |
|------------------------------------|------------|-----|-----------------------|-----------------|---------------------|-----------|------------------------|---------|----------|---------------|
| Cavalcanti et al. (2020) [63]      | case series| 1 (of 3) | C-19                  | 10              | TP (141 T/uL), elevated D-dimer levels (>55,000 ng/mL) | edema, rapid deterioration | MT (A) plus LT (micro-catheter, cont.) | 6       | partial  | SSS, TS, SS, DV | NN |
| Omari et al. (2022) [64]           | case report| 1   | C-19                  | 30              | NN                  | visual deterioration, intracranial hypertension | NN       | NN       | NN            | TS, S Sig | blindness |
| Sajjad et al. (2021) [65]          | case report| 1   | C-19                  | 20              | TP (NN), PF4 antibodies (NN), elevated D-dimer levels (6.3 mg/L) | ICH plus edema, coma, deterioration | Fogarty catheter | 2       | full     | SSS          | NN |
| Chew et al. (2021) [66]            | case series| 6   | VITT (ChAdOx1 nCoV-19) | 10 (~14) | TP (11 T-91 T/uL), PF4 antibodies and D-dimer levels NN | ICH (n = 5), progressive thrombus material, deterioration (coma) | Aspiration (Penumbra) | 0-1: n = 3; 6: n = 2, satisf. (n = 5) | NN | n = 1 (ICH-progression) |
| Wolf et al. (2021) [67]            | case series| 3   | VITT (ChAdOx1 nCoV-19) | 4 (~17) | TP (60 T-92 T/uL), PF4 antibodies (positive), elevated D-dimer levels (2120-22,800 ng/mL) | SAH (1); ICH (2); coma due to bilateral thalamic edema (3) | MT (A [1, 3] plus B [2]) | 0 (1, 3); 1 (2) | full | SSS, TS (1), SSS, TS Sig (2) | 2 MT sessions needed (2) |
| Cleaver at al. (2021) [68]         | case series| 3   | VITT (ChAdOx1 nCoV-19) | 8 (~27) | TP (85 T/uL [1], 23 T/uL [2], 35 T/uL [3]); PF4-antibodies positive (all), elevated D-dimer levels (15.83-30.34 µg/mL) | progr. ICH/SAH, edema and deterioration (1); progr. ICH and thrombus material (2); new ICH, status epileptics, intubation (3) | MT (A [1, A plus SR [2]) | 2 (all) | full, partial (1, 3) | SSS (1), S, SS Sig, TS (2), SSS, SS Sig, TS (3) | NN |
| Gurjar et al. (2022) [69]          | case report| 1   | VITT (mRNA-1273 vaccine)** | 3 months | TP (139 T/uL), PF4 antibodies (negative), elevated D-dimer levels (16.666 ng/mL) | coma, progressive symptoms | MT (not specified) | 3       | full     | SSS, TS, SS Sig | NN |
| Mirandola et al. (2022) [70]       | case report| 1   | VITT (ChAdOx1 nCoV-19) | 15              | TP (40 T/uL), PF4 antibodies (positive), elevated D-dimer levels (18 mcg/mL) | progressive thrombus material, edema, coma and seizure requiring intubation | MT (A plus SR) | 0       | partial (SS), full (rest) | SSS, SS, TS, SS Sig | NN |
| Choi et al. (2021) [71]            | case report| 1   | VITT (ChAdOx1 nCoV-19) | 12              | TP (14 T/uL), PF4 antibodies (positive), elevated D-dimer levels (>32.5 mg/L [reference: >0.5]) | progressive coma | MT (not specified) | 6       | full     | S Sig | NN |
| Waraich et al. (2021) [72]         | case report| 1   | VITT (ChAdOx1 nCoV-19) | 13              | TP (14 T/uL), PF4 antibodies NN, elevated D-dimer levels (62.342 ng/mL) | deterioration, SAH, seizures requiring CPR | NN       | NN (2 ***) | full | SSS, TS, SS Sig | NN |

*ChAdOx1 nCoV-19, AstraZeneca vaccine; ** mRNA-1273 vaccine, Moderna; *** not specified, mRS assumed by the authors depending on the symptom description provided; n, number; VITT, vaccine-induced thrombotic thrombocytopenia; d, days; mRS, modified Rankin Scale; TP, thrombocytopenia; PF4, platelet factor 4; T, thousand; ICH, intracerebral hemorrhage; SHA, subarachnoid hemorrhage; CPR, cardiopulmonary resuscitation; NN, unknown; SSS, sagittal superior sinus; SS, straight sinus; S Sig, sigmoid sinus; SS, transverse sinus; DV, deep cerebral veins; SVT, sinus or cerebral vein thrombosis; MT, mechanical thrombectomy; LT, local (intracranial) thrombolysis; A, aspiration thrombectomy; SR, stent retriever thrombectomy; B, balloon guided thrombectomy or angioplasty; cont, continuous.
4. Discussion

The overall outcome after SVT can be unfavorable in terms of functional independence and survival [8,11,72]. A total of 75–84% of patients eventually become functionally independent, with excellent functional recovery (mRS, 0–1) [8,11,72]. However, a considerable number of patients remain functionally dependent or disabled (22.2%) or die (up to 14.6%) [11,72]. To identify patients prone to poor prognosis, several risk factors have been identified (independent of treatment strategies): GCS < 9, presence of ICH, involvement of the deep cerebral venous system, mental status disorder (not specified; additional conditions such as underlying malignancy, cerebral or systemic infection, and requirement for hemicraniectomy also apply) [11,72–74]. Neurological deterioration—as part of the natural course of the disease or due to factors such as heparin resistance—might necessitate an additional EVT approach to remove the thrombus load [75].

Retrospective and anecdotal data have demonstrated the safety and feasibility of EVT in selected patients, and have shown satisfying results [19,39–57]. Yet, because of their lack of a control group and their retrospective nature, those studies have been unable to demonstrate a treatment effect resulting in an outcome benefit. In addition, inconsistencies in the timing of the interventions, indications for surgical procedures such as decompressive hemicraniectomy, etiological considerations (e.g., malignancy or sepsis) and clinical complications interfering with outcomes (e.g., status epilepticus) make an interpretation difficult. To our knowledge, only one RCT (TO-ACT) has compared EVT to standard care in patients with SVT (again, with a suspected unfavorable prognosis, as described above). TO-ACT did not detect a modification of the treatment effect attributable to EVT (see Table 1 for inclusion criteria) [38]. The limitations of this trial include its small sample size (due to early termination recommended by the data and safety monitoring board because of futility), patient selection based on clinical presentations suspected to (and previously reported to) negatively influence outcomes and unrestricted use of available endovascular approaches and devices [38]. Therefore, non-significant but clinically relevant treatment effects as well as subgroups that might actually show considerable benefits remained undetected. In a meta-analysis using individual patient data (not including RCT data), EVT was associated with poor outcomes and mortality [76]. Because each treatment decision was made individually in each case (no clear indication; suspected poor prognosis), generalizability is limited. The baseline characteristics were poorer in EVT patients than in controls. Therefore, these retrospective results must be interpreted very cautiously. Important questions regarding patient selection (clinical versus imaging characteristics) and the timing of the intervention remain unanswered. Waiting until a patient is deteriorating might be too late.

Various treatment strategies have been investigated in EVT for SVT. Local thrombolytic therapy (urokinase or alteplase) was performed in most of the cases [19,38–42,44–49,51–57], with either a single perinterventional bolus or a continual infusion (locally, via a microcatheter) for up to 72 h (or longer, depending on the recanalization success). Yue et al. (2010) combined intraarterial thrombolysis with an endovascular thrombectomy approach (balloon-guided) [57]. Several thrombectomy procedures were discussed in the presented literature: aspiration thrombectomy [19,38–42,46,48,49,51,53–56], stent retriever thrombectomy [38–42,46–49,54], balloon-guided thrombectomy/angioplasty [19,38–41,44,47,51,53,54,57], the (rheolytic) AngioJet device [38–40,47,49,50] as well as additional stenting [42,46]. The study by Dashti et al. was the only one performing thrombectomy without local thrombolysis (AngioJet) [50]. A meta-analysis published in 2019 did not detect differences in outcomes stratified by treatment approach [77]. Despite poor baseline characteristics, 70–80% of patients eventually achieved mRS scores of 0–2 in the follow-up [78]. Local thrombolysis in combination with EVT has not been associated with the development or worsening of an ICH (complication rate < 10%) [78]. Further complications observed were subarachnoid hemorrhage, vessel perforation, and treatment failure [38–42,50,52,54]. Experience and routine (i.e., adherence to a local protocol) might be important because centers following one specific approach showed higher recanalization rates (independently of the procedure or the combination of procedures chosen) than centers using various
combinations of EVT strategies [77]. However, the described inconsistencies in device allocation and the small number of treated patients make comparisons regarding the superiority of any of the treatment strategies impossible. Thus, future trials are needed to make such a comparison. Endovascular trials in acute ischemic stroke have indicated that devices are crucial in facilitating treatment effects, recanalization rates, and good functional outcomes [79].

Both COVID-19 and COVID-19 vaccination have been reported to be associated with an increase in SVT incidence [5,6]. Patients with COVID-associated SVT (4.2% of all COVID-associated strokes) appear to be older, do not have specific risk factors and experience higher in-hospital mortality (up to 16.7%) [80,81]. In a New York cohort study, two of the 12 patients received endovascular local thrombolysis [5]. SVT associated with COVID-19 vaccination may be more severe and has higher reported mortality rates (39.2% as compared with approximately 2–5% in pre-pandemic SVT) [6]. The mechanism of pathogenesis (VITT; a prothrombotic state associated with an immunoglobin G reaction against PF4) predominantly occurs in adenovirus vector-type vaccinations (ChAdOx1 nCov-19 (AstraZeneca); recombinant adenovirus type 26 vector encoding S glycoprotein of SARS-CoV-2 (Johnson and Johnson/Janssen)) [6,82]. EVT might be reasonable in selected patients meeting the TO-ACT inclusion criteria (Table 1) [38,83]. Although observational data and case reports of EVT in those patients are scarce [65–71], these studies have indicated the feasibility and safety of EVT and have suggested that EVT can achieve good functional outcomes in a cohort with overall poor prognosis.

This systematic review is limited by the quality (and sample size) of the available data. The disadvantages of the TO-ACT trial have already been discussed. Because of the retrospective design of the remaining data, all the attributed limitations apply (e.g., selection bias or bias by indication) because the rationale for treatment allocation and the number of patients who were potentially eligible for treatment but were not considered are unknown. Therefore, the presented results and the conclusion require very cautious interpretation.

In conclusion, the available data do not support the routine use of EVT strategies in patients with SVT. In patients with a suspected poor outcome (meeting the TO-ACT inclusion criteria), EVT can be performed as part of individual healing attempts. EVT is feasible and safe and might possibly improve functional outcomes. No reasonable recommendation can be made regarding which endovascular technique to use (and in which cases). According to our own experience, patients with substantial thrombus material (without an early response to anticoagulation), those with ICH, those in need of intensive care, and those with VITT do benefit from EVT. Yet, whether patients with clinical and/or imaging risk factors might benefit from early treatment initiation (before deterioration occurs) remains unknown. Further RCTs are warranted to investigate treatment strategies, patient selection, and the timing of the intervention (using predefined therapeutic strategies and reproducible inclusion criteria).

Author Contributions: P.B. and H.H.: drafted the article and performed the primary literature research. P.B. wrote the manuscript. V.H.: expert in the endovascular treatment of intracranial venous sinus thrombosis, involved in the data collection and analysis of data concerning endovascular management. A.C.: expert in the endovascular treatment of intracranial venous sinus thrombosis, involved in the data collection and analysis of data concerning the outcome of different endovascular procedures. J.E.C.: endovascular neurosurgeon, contributed to aspects of endovascular and intensive care treatment concepts. T.H.: neurologist with significant stroke experience, analyzed the manuscript concerning the medicinal treatment of VST. O.G.: senior neurosurgeon with significant neurovascular experience, supervised the aspects of surgical treatment of VST. H.B.: senior neurologist with significant stroke experience, supervised the aspects of medicinal treatment of VST. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
Data Availability Statement: There are no data beyond the analyzed publications, which became the basis for this systematic review.

Conflicts of Interest: H.H. is coinventor of the Solitaire stent and the pRESET stent retriever and co-founder of phenox GmbH, femtos GmbH and CONTARA GmbH, which are medical device companies developing and/or selling products for the EVT of neurovascular disorders. All other authors declare no conflicts of interest in the context of this publication.

References

1. Hopper, A.H.; Klein, J.P. Cerebral Venous Thrombosis. *N. Engl. J. Med.* 2021, 385, 59–64.
2. Bousser, M.; Ferro, J.M. Cerebral venous thrombosis: An update. *Lancet Neurol.* 2007, 6, 162–170. [CrossRef]
3. Coutinho, J.M.; Zuurbier, S.M.; Aramideh, M.; Stam, J. The Incidence of Cerebral Venous Thrombosis a Cross-Sectional Study. *Stroke* 2012, 43, 3375–3377. [CrossRef]
4. Stam, J. Thrombosis of the Cerebral Veins and Sinuses. *N. Engl. J. Med.* 2005, 352, 1791–1798. [CrossRef]
5. Al-Mufti, F.; Amuluru, K.; Sahni, R.; Bekelis, K.; Karimi, R.; Ogulnick, J.; Cooper, J.; Overby, P.; Nuoman, R.; Tiwari, A.; et al. Cerebral Venous Thrombosis in COVID-19: A New York Metropolitan Cohort Study. *AJNR Am. J. Neuroradiol.* 2021, 42, 1196–1200. [CrossRef]
6. Lee, S.-K.; Mokin, M.; Hetts, S.W.; Fifi, J.F.; Bousser, M.; Fraser, J.F.; Society of NeuroInterventional Surgery. Current endovascular strategies for cerebral venous sinus thrombosis: A systematic review. *J. Prim. Care Community Health* 2022, 13, 1–10. [CrossRef]
7. Jung, S.; Mattle, H.; Horvath, T.; Seifgø, D.; Heldner, M.; Meinel, T.; Bühlmann, M.; Prange, U.; Salmen, S.; Humm, A.; et al. Stroke Guidelines of the Bern Stroke Network. Available online: http://www.neurologie.insel.ch/fileadmin/Neurologie/Dokumente/Stroke_Center/Stroke_Guidelines_2021.English.pdf (accessed on 26 May 2022).
8. Devianne, J.; Legris, N.; Crassard, I.; Bellesme, C.; Bejot, Y.; Guidoux, C.; Pico, F.; Germaud, D.; Obadia, M.; Rodriguez, D.; et al. Epidemiology, Clinical Features, and Outcome in a Cohort of Adolescents with Cerebral Venous Thrombosis. *Neurology* 2021, 97, e1920–e1932. [CrossRef]
9. Einhäupl, K.M.; Villringer, A.; Meister, W.; Mehraein, S.; Canhão, P.; Falcao, F.; Ferro, J.M. Thrombolysis or anticoagulation for cerebral venous thrombosis: Rationale and design of the TO-ACT trial. *Int. J. Stroke* 2013, 8, 135–140. [CrossRef] [PubMed]
10. De Bruijn, S.F.T.M.; Stam, J.; for the Cerebral Venous Sinus Thrombosis Study Group. Randomized, Placebo-Controlled Trial of Anticoagulant Treatment with Low-Molecular-Weight Heparin for Cerebral Sinus Thrombosis. *Stroke* 1999, 30, 484–488. [CrossRef]
11. Ferro, J.M.; Canhão, P.; Stam, J.; Bousser, M.; Barinagarrementeria, F.; ISCVT Investigators. Prognosis of Cerebral Vein and Dural Sinus Thrombosis Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). *Stroke* 2004, 35, 664–670. [CrossRef]
12. Lee, S.-K.; Mokin, M.; Hetts, S.W.; Fifi, J.F.; Bousser, M.; Fraser, J.F.; Society of NeuroInterventional Surgery. Current endovascular strategies for cerebral venous sinus thrombosis: Report of the SNIS Standards and Guidelines Committee. *NeuroInterv. Surg.* 2018, 10, 803–810. [CrossRef] [PubMed]
13. Coutinho, J.M.; Ferro, J.M.; Zuurbier, S.M.; Mink, M.S.; Canhão, P.; Crassard, I.; Majoie, J.B.; Reekers, J.A.; Houdart, E.; de Haan, R.J.; et al. Thrombolysis or anticoagulation for cerebral venous thrombosis: Rationale and design of the TO-ACT trial. *Int. J. Stroke* 2013, 8, 135–140. [CrossRef] [PubMed]
14. Simaan, N.; Molad, J.; Peretz, S.; Filigolo, A.; Auriel, E.; Hallevi, H.; Seyman, E.; Barnea, R.; Cohen, J.E.; Leker, R.R.; et al. Characteristics of Cerebral Sinus Venous Thrombosis Patients Presenting with Intracerebral Hemorrhage. *J. Clin. Med.* 2022, 11, 1040. [CrossRef]
15. Rahman, M.; Velat, G.J.; Hoh, B.L.; Mocco, J. Direct thrombolysis for cerebral venous sinus thrombosis. *Neurosurg. Focus* 2009, 27, E7. [CrossRef] [PubMed]
16. Baker, M.D.; Opatowsky, M.J.; Wilson, J.A.; Glazier, S.S.; Morris, P.P. Rheolytic catheter and thrombolysis of dural venous sinus thrombosis: A case series. *Neurosurgery* 2013, 48, 487–493. [CrossRef] [PubMed]
17. Canhão, P.; Falcao, F.; Ferro, J.M. Thrombolytics for cerebral sinus thrombosis: A systematic review. *Cereb. Dis* 2003, 15, 159–166. [CrossRef] [PubMed]
18. Choulakian, A.; Alexander, M.J. Mechanical thrombectomy with the penumbra system for treatment of venous sinus thrombosis. *J. Neurointerv. Surg.* 2010, 2, 153–156. [CrossRef]
19. Jankowitz, B.T.; Bodily, L.M.; Jumaa, M.; Syed, Z.F.; Jovin, T.G. Manual aspiration thrombectomy for cerebral venous sinus thrombosis. *J. Neurointerv. Surg.* 2013, 5, 534–538. [CrossRef]
20. Kirsch, J.; Rasmussen, P.A.; Masaryk, T.J.; Perl, J., II; Fiorella, D. Adjunctive rheolytic thrombectomy for chronic sinus venous thrombosis: Technical case report. *Neurosurgery* 2007, 60, E577–E578. [CrossRef]
21. La Barge, D.V.; Bishop, F.S.; Stevens, E.A.; Eskandari, R.; Schmidt, R.H.; Skalabrin, E.J.; Ng, P.P. Intrasinus catheter-directed heparin infusion the treatment of dural venous sinus thrombosis. *AJNR Am. J. Neuroradiol.* 2009, 30, 1672–1678. [CrossRef]
22. Zhang, A.; Collinson, R.L.; Hurst, R.W.; Weigele, J.B. Rheolytic thrombectomy for cerebral sinus thrombosis. *Neurocrit Care* 2008, 9, 17–26. [CrossRef] [PubMed]
47. Qureshi, A.I.; Grigoryan, M.; Saleem, M.A.; Aytaç, E.; Wallery, S.S.; Rodriguez, G.J.; Suri, M.F.K. Prolonged Microcatheter-Based Local Thrombolytic Infusion as a Salvage Treatment After Failed Endovascular Treatment for Cerebral Venous Thrombosis: A Multicenter Experience. *Neurocrit Care* **2018**, *29*, 54–61. [CrossRef]

48. Styczen, H.; Tsogkas, I.; Liman, J.; Maus, V.; Psychogios, M.N. Endovascular Mechanical Thrombectomy for Cerebral Venous Sinus Thrombosis: A Single-Center Experience. *World Neurosurg.* **2019**, *127*, e1097–e1103. [CrossRef]

49. Mokin, M.; Lopes, D.K.; Binning, M.J.; Veznedaroglu, E.; Liebman, K.M.; Arthur, A.S.; Doss, V.T.; Levy, E.I.; Siddiqui, A.H. Endovascular treatment of cerebral venous thrombosis: Contemporary multicenter experience. *Interv Neuroradiol.* **2015**, *21*, 520–526. [CrossRef]

50. Dashti, S.H.; Hu, V.C.; Fiorella, D.; Mitha, A.P.; Abuquerque, F.C.; McDougall, C.G. Mechanical thrombectomy as first-line treatment for venous sinus thrombosis: Technical considerations and preliminary results using the AngioJet device. *J. Neurointerv. Surg.* **2011**, *5*, 49–53. [CrossRef]

51. Lee, C.; Liu, H.; Chen, Y.; Lin, Y.; Wang, J. Suction thrombectomy after balloon maceration for dural venous sinus thrombosis. *J. Neurol. Sci.* **2016**, *365*, 76–81. [CrossRef]

52. Poulsen, F.R.; Hegedal, L.; Stilling, M.V.; Birkeland, P.F.; Schultz, M.K.; Rasmussen, J.N. Good clinical outcome after combined endovascular and neurosurgical treatment of cerebral venous sinus thrombosis. *Dan. Med. J.* **2013**, *60*, A4724. [PubMed]

53. Mammen, S.; Keshava, S.N.; Moses, V.; Aaron, S.; Ahmed, M.; Chiramel, G.K.; Mani, S.E.; Alexander, M. Role of penumbra mechanical thrombectomy device in acute dural sinus thrombosis. *Indian J. Radiol. Imaging* **2017**, *27*, 82–87. [CrossRef] [PubMed]

54. F.; Dan, B.; Zhang, Z.; Zhu, B.; Liu, J. Efficacy of Stent Thrombectomy Alone or Combined with Intermediate Catheter Aspiration for Severe Cerebral Venous Sinus Thrombosis: A Case-Series. *Front. Neurol.* **2021**, *12*, 783380. [CrossRef]

55. Medhi, G.; Parida, S.; Nicholson, P.; Senapati, S.B.; Padhy, B.P.; Medes Pareira, V. Mechanical Thrombectomy for Cerebral Venous Sinus Thrombosis: A Case Series. *World Neurosurg.* **2020**, *140*, 148–161. [CrossRef]

56. Tsang, A.C.O.; Hwang, A.C.; Chiu, R.H.Y.; Chan, D.Y.C.; Tsang, F.C.P.; Ho, W.S.; Lee, R.; Leung, G.K.K.; Lui, W.M. Combined aspiration thrombectomy and continuous intrasinus thrombolysis for cerebral venous sinus thrombosis: Technical note and case series. *Neuroradiology* **2018**, *60*, 1093–1096. [CrossRef] [PubMed]

57. Yue, X.; Xi, G.; Zhou, Z.H.; Xu, G.; Liu, X. Combined intraarterial and intravenous thrombolysis for severe cerebral venous sinus thrombosis. *J. Thromb. Thrombolysis* **2010**, *29*, 361–367. [CrossRef]

58. Saposnik, G.; Barinagarrementeria, F.; Brown, R.D., Jr.; Bushnell, C.D.; Cucchiara, B.; Cushman, M.; deVeber, G.; Ferro, J.M.; Tsai, F.Y. American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and Management of Cerebral Venous Thrombosis A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. *Stroke* **2011**, *42*, 1158–1192. [CrossRef]

59. Ferro, J.M.; Bousser, M.; Canhão, P.; Coutinho, J.M.; Crassard, I.; Dentali, F.; Di Minno, M.; Maino, A.; Martinelli, I.; Masuhr, F.; et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis—Endorsed by the European Academy of Neurology. *Eur. J. Neurol.* **2017**, *24*, 1203–1213. [CrossRef]

60. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shrameer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennarn, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *J. Clin. Epidemiol.* **2021**, *134*, 178–189. [CrossRef]

61. Ostovan, V.R.; Foroughi, R.; Rostami, M.; Almasi-Dooghaei, M.; Esmaili, M.; Akbar Bidaki, A.; Behzadi, Z.; Farzadfard, F.; Marbooth, H.; Rahimi-Jaberi, A.; et al. Cerebral venous sinus thrombosis associated with COVID-19: A case series and literature review. *J. Neurol. Sci.* **2021**, *426*, 3549–3560. [CrossRef]

62. Cavalcanti, D.D.; Raz, E.; Shapiro, M.; Dekhkarhan, S.; Yaghi, S.; Lillemore, K.; Nossek, E.; Torres, J.; Jain, R.; Riina, H.A.; et al. Cerebral Venous Thrombosis Associated with COVID-19. *AJR Am. J. Neuroradiol.* **2020**, *41*, 1370–1376. [CrossRef] [PubMed]

63. Omari, A.; Kally, P.; Schimmel, O.; Kahana, A. Vision Loss Secondary to COVID-19 Associated Bilateral Cerebral Venous Sinus Thromboses. *Ophthalmic Plast. Reconstr. Surg.* **2022**, *38*, e65–e67. [CrossRef] [PubMed]

64. Sajjad, A.; Khan, A.F.; Jafari, L.; Kamal, A.K. Successful endovascular mechanical thrombectomy in anticoagulation-resistant COVID-19 associated cerebral venous sinus thrombosis. *BMJ Case Rep.* **2021**, *14*, e245405. [CrossRef]

65.检查, H.S.; Al-Ali, S.; Butler, B.; Rajapakse, D.; Nader, S.K.; Chavda, S.; Lamin, S. Mechanical Thrombectomy for Treatment of Cerebral Venous Sinus Thrombosis in Vaccine-Induced Immune Thrombocytopenia. *AJNR Am. J. Neuroradiol.* **2022**, *43*, 98–101. [CrossRef] [PubMed]

66. wolf, M.E.; Suz, B.; Niehaus, L.; Bhogal, P.; Bänzler, H.; Henkes, H. Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure. *J. Clin. Med.* **2021**, *10*, 1599. [CrossRef] [PubMed]

67. Cleaver, J.; Ibitoye, R.; Morrison, H.; Flood, R.; Crewedson, K.; Marsh, A.; Abhinav, K.; Bosnell, R.; Crossley, R.; Mortimer, A. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccination: A report of three cases. *J. Neurol. Sci.* **2021**, *41*, 1–6. [CrossRef]

68. Gurjar, H.; Dhallu, M.; Lvovsky, D.; Sadullah, S.; Chilimuri, S. A Rare Case of Coronavirus Disease 2019 Vaccine-Associated Cerebral Venous Sinus Thrombosis Treated with Mechanical Thrombectomy. *Am. J. Case Rep* **2022**, *23*, e935355. [CrossRef]

69. Miranda, L.; Arena, G.; Pagliaro, M.; Boghi, A.; Naldi, A.; Castellano, D.; Vaccarino, A.; Silengo, D.; Aprà, F.; Cavallo, R.; et al. Massive cerebral venous sinus thrombosis in vaccine-induced immune thrombocytopenic thrombosis after ChAdOx1 nCoV-19 serum: Case report of a successful multidisciplinary approach. *Neuroli. Sci.* **2022**, *43*, 1499–1502. [CrossRef]
70. Chou, J.; Kim, S.; Kim, S.R.; Jin, J.Y.; Choi, S.W.; Kim, H.; Yoo, J.H.; Park, I.S.; Kim, S.R. Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: The First Fatal Case in Korea. J. Korean Med. Sci. 2021, 36, e223. [CrossRef]

71. Waraich, A.; Williams, G. Haematuria, a widespread petechial rash, and headaches following the Oxford AstraZeneca ChAdOx1 nCoV-19 Vaccination. BMJ Case Rep. 2021, 14, e25440. [CrossRef]

72. Karsy, M.; Harmer, J.R.; Guan, J.; Brock, A.A.; Ravindra, V.M.; Chung, L.S.; Tkach, A.; Majersik, J.J.; Park, M.S.; Schmidt, R.H. Outcomes in adults with cerebral venous sinus thrombosis: A retrospective cohort study. J. Clin. Neurosci. 2018, 53, 34–40. [CrossRef]

73. Yeo, L.L.L.; Lye, P.P.S.; Yee, K.W.; Cuni, Y.; Ming, T.T.; Ho, A.F.; Sharma, V.K.; Chan, B.P.; Tan, B.Y.; Gopinathan, A. Deep Cerebral Venous Thrombosis Treatment Endovascular Case using Aspiration and Review of the Various Treatment Modalities. Clin. Neuroradiol. 2020, 30, 661–670. [CrossRef] [PubMed]

74. Pfefferkorn, T.; Crassard, I.; Linn, J.; Dichgans, M.; Boukobza, M.; Bousser, M. Clinical features, course and outcome in deep cerebral venous system thrombosis: An analysis of 32 cases. J. Neurol. 2009, 256, 1839–1845. [CrossRef] [PubMed]

75. King, A.B.; O’Duffy, A.E.; Kumar, A.B. Heparin Resistance and Anticoagulation Failure in a Challenging Case of Cerebral Venous Sinus Thrombosis. Neurohospitalist 2015, 6, 118–121. [CrossRef]

76. Xu, Z.; Li, X.; Feng, D.; Wang, T.; Xu, X.; Deng, R.; Zhou, X.; Chen, G. Endovascular Therapy Versus Anticoagulation for Treatment of Cerebral Venous Sinus Thrombosis A Meta-Analysis. Neurologist 2022, 27, 69–73. [CrossRef]

77. Lewis, W.; Saber, H.; Sadeghi, M.; Rajah, G.; Narayanan, S. Transvenous Endovascular Recanalization for Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. World Neurosurg. 2019, 130, 341–350. [CrossRef] [PubMed]

78. Ilyas, A.; Chen, C.H.-J.; Raper, D.M.; Ding, D.; Buell, T.; Mastorakos, P.; Liu, K.C. Endovascular mechanical thrombectomy for cerebral venous sinus thrombosis: A systematic review. J. Neurointerv. Surg. 2017, 9, 1086–1092. [CrossRef]

79. Boyle, K.; Joundi, R.A.; Aviv, R.I. An historical and contemporary review of endovascular therapy for acute ischemic stroke. Neurovasc Imaging. 2017, 3, 1. [CrossRef]

80. Shahjouei, S.; Tsivgoulis, G.; Farahmand, G.; Koza, E.; Mowla, A.; Sadr, A.V.; Kia, A.; Far, A.V.; Mondello, S.; Cernigliaro, A.; et al. SARS-CoV-2 and Stroke Characteristics A Report from the Multinational COVID-19 Stroke Study Group. Stroke 2021, 52, e117–e130. [CrossRef]

81. Mowla, A.; Shakibajahromi, B.; Shahjouei, S.; Borhani-Haghighi, A.; Rahimian, N.; Baharvadhat, H.; Naderi, S.; Khorvash, F.; Altafi, D.; Ebrahimzadeh, S.A.; et al. Cerebral venous sinus thrombosis associated with SARS-CoV-2: a multinational case series. J. Neurol. Sci. 2020, 419, 117183. [CrossRef]

82. McGonagle, D.; De Marco, G.; Bridgewood, C. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. J. Autoimmun. 2021, 121, 102662. [CrossRef] [PubMed]

83. Mahajan, A.; Hirsch, J.A. Cerebral venous thrombosis after COVID-19 vaccination: The role for endovascular treatment. J. NeuroInterv. Surg. 2022, 1–2. [CrossRef] [PubMed]